Tempus AI CEO Eric Lefkofsky: Healthcare will likely be the biggest beneficiary of AI
Speakers
Eric Lefkofsky
— Founder and CEO, Tempus AI; Managing Partner, Lightbank Capital
Summary
Eric Lefkofsky of Tempus AI argues that healthcare is likely to be the biggest eventual beneficiary of AI because frontier models are well suited to messy clinical data. He highlights Tempus AI's diagnostics and data businesses, its large dataset, and its early scaling of AI models. He also points to Merck and Moderna's personalized cancer vaccine as a promising step toward personalized immunotherapies. The segment opens with Anthropic IPO chatter and touches on whether slowing AI development would affect healthcare AI efforts.
- Eric Lefkofsky says healthcare may be AI's biggest beneficiary.
- He cites AI's fit for unstructured, disparate healthcare data.
- Tempus AI operates diagnostics and data businesses with a large dataset.
- Tempus has been scaling frontier AI models for years.
- Merck/Moderna personalized cancer vaccine is framed as a major example.
- Lefkofsky says the trial success was dramatic and more readouts may come.
- The interview begins with Anthropic IPO details and AI slowdown debate.
- The transcript ends mid-discussion on enterprise AI model power.
Ideas
Healthcare is AI's biggest eventual beneficiary.
Healthcare is likely to be the biggest eventual beneficiary of AI because frontier models are especially good at making sense of unstructured, disparate, and messy healthcare data, and the application—helping people live longer and healthier lives—is highly valuable.
Tempus AI is built for AI healthcare.
Tempus AI has two core businesses—diagnostics and data—that use large datasets and AI to make diagnostics smarter and help drug companies develop better drugs. The company has amassed a large dataset, and frontier models were perfectly designed to help both businesses, with Tempus actively scaling these models for the past three to four years.
Merck/Moderna personalized cancer vaccine shows promise.
Merck and Moderna's personalized cancer vaccine is a major example of moving from targeted to personalized therapies: sequencing a patient and building a drug based on that person's unique molecular and immune profile could make immunotherapies effective in patients who do not respond. The trial success was dramatic, and the companies have suggested more readouts are coming, supporting excitement across the space.
